No. 182 April 13, 2018

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (MDH), **Maryland Medicaid Pharmacy Program** (MMPP) has developed the **Maryland Medicaid Pharmacy Program Advisory**. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the MMPP representative at 410-767-1455.

## Brand vs Generic (DAW 6) Changes on Maryland's Preferred Drug List

The Maryland Medicaid Pharmacy Program (MMPP) wants to alert you that **effective Friday**, **April 27 2018**, the following changes will occur in the brand vs generic (DAW 6) drug program.

- Brand Prevacid Solutabs® is preferred over its generic equivalent lansoprazole ODT. Claims for brand Prevacid Solutabs®
  must be submitted with DAW code of 6 and will be priced appropriately. Claims with any other DAW code will reject. A MDH
  Medwatch form will not be required.
- Brand Emend® capsules are no longer preferred over its generic equivalent, aprepitant capsules. Claims for aprepitant capsules will be handled in the same manner as claims for other multisource drugs. Fee-for-service Medicaid claims for brand Emend® capsules will adjudicate only if there is prior authorization based on an approved MDH Medwatch form which can be found at the following link: <a href="https://mmcp.health.maryland.gov/pap/docs/Maryland%20Medwatch%20Form.pdf">https://mmcp.health.maryland.gov/pap/docs/Maryland%20Medwatch%20Form.pdf</a>

Please refer to our website for a complete list of the PDL at the following link: https://mmcp.health.maryland.gov/pap/docs/Maryland%20PDL%201.1.18.pdf